Our Passion, Your Health.

2017

28 June 2017

FIDIA PHARMA USA Inc. Continues to Expand U.S. Presence as Fidia Farmaceutici S.p.A. Leads European Orthopedic Biomaterials Market

Global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021
PARSIPPANY, N.J., June 28, 2017 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA Inc., are projecting continued growth in 2017. The global viscosupplementation market is anticipated

8 May 2017

HYMOVIS®: An Innovation In Ha-Based Viscoelastic Hydrogel Technology In The Treatment Of Osteoarthritis Knee Pain

PARSIPPANY, NJ, May 8, 2017 - Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA) - based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces their presence at the American Medical Society for Sports Medicine (AMSSM) 2017 Annual Meeting with an educational symposium on Thursday, May

22 March 2017

HYMOVIS® Demonstrates Superior Biomechanical Lubricating Properties

HYMOVIS® has exceptional lubricating properties in moving cartilage to a low-friction regime. The study provides a unifying framework to evaluate the potential clinical efficacy of injectable hyaluronic acid therapies.
PARSIPPANY, NJ., March 22, 2017 - Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA) - based products and its

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

Have Knee Pain?

Diagnosed with OSTEOARTHRITIS (OA) of the knee?

You may be eligible to participate in a clinical trial